FELLOWSHIPS, AWARDS AND HONORS

Transcription

1 Laura Faden Garabedian 1930 Chestnut St., Apt. 20B Philadelphia, PA (508) EDUCATION Harvard University, Cambridge, MA ( ) Ph.D. in Health Policy (Evaluative Sciences and Statistics) Dissertation: Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance Coverage and Methods for Comparative Effectiveness Research (3 papers) Impact of Universal Health Insurance Coverage in Thailand on Sales and Market Share of Medicines for Non-Communicable Diseases Massachusetts Health Care Reform: Impact of the Individual Mandate and Health Insurance Exchange on Short-term Enrollment and Adverse Selection The Invalidity of the Most Common Instrumental Variable Analyses in Comparative Effectiveness Research Committee: Stephen Soumerai (chair), Anita Wagner, Alan Zaslavsky Tufts University School of Medicine, Boston, MA ( ) M.P.H. (Health Services Management and Policy), delta omega Boston University, College of Arts and Sciences, Boston, MA (2001- Jan. 2005) B.A. in Psychology, summa cum laude RESEARCH INTERESTS Health Services Research, Health Economics I am interested in the empirical evaluation of health policies and programs, with a focus on health system organization, health financing, and health care delivery. Key areas of interest include: global and domestic health insurance reform, health care delivery innovations, pharmaceutical policy, and comparative effectiveness research. I am also interested in the evaluation and development of analytic methods for health policy research, with a particular focus on observational data methods. FELLOWSHIPS, AWARDS AND HONORS Thomas O. Pyle Post-Doctoral Fellowship, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute 2013 Joan P. Curhan Citizenship Award for the PhD Program in Health Policy Harvard University Dissertation Completion Fellowship 2012 First Place Ribbon, 2012 Association for Public Policy Analysis and Management (APPAM) Fall Research Conference Poster Awards US Agency for Healthcare Research and Quality (AHRQ) Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Network project grant Alfred P. Sloan Foundation Fellowship in Managed Care 2011 Harvard University Certificate of Distinction in Teaching Pharmaceutical Policy Research Fellowship, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute 2010 Harvard Graduate Society Summer Pre-dissertation Research Fellowship US Agency for Healthcare Research and Quality (AHRQ) Pre-doctoral Trainee 2009 Drug Information Journal's Student Award (for excellence in publishing by a student contributor) 2008 Delta Omega (Honorary Society of Public Health) 2008 Selected to represent Tufts at the Massachusetts Health Policy Student Forum Garabedian 1

2 2005 Phi Beta Kappa Honor Society 2004 Stratus Technologies Scholarship 2004 Harold. C. Case Scholarship, Boston University, Awarded annually to ten BU juniors who exhibit great scholarly accomplishment and potential, as well as participate in extracurricular activities that contribute to University life Second Place Ribbon, Boston University Undergraduate Public Health Poster Forum Dean s List every semester, Boston University RESEARCH EXPERIENCE June Department of Population Medicine present Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA Research Fellow, Project Consultant Feb Tufts Center for the Study of Drug Development, Tufts University, Boston, MA - July 2008 Senior Research Analyst (promoted from Research Assistant in 2006) Jan May 2008 Massachusetts Health Insurance Connector Authority, Boston, MA Research Intern (fieldwork component of Tufts MPH program) Oct The New Health Network, London, England - Dec Research Intern (Boston University study abroad and internship program) June 2003 Center for Anxiety and Related Disorders, Boston University, Boston, MA - June 2005 Research Assistant to Dr. Kamila White, Director of Behavioral Medicine Program TEACHING EXPERIENCE Teaching Fellowships Sept PhD Core Course in Health Policy (HLTHPOL2000), Harvard University May 2011 Teaching Fellow for Professors Joseph Newhouse, Alan Zaslavsky and David Cutler Jan May 2010 Sept Dec Global Health Challenges: Complexities of Evidence-based Policy (SW-24), Harvard College Teaching Fellow for Dr. Sue Goldie Advanced Quantitative Methods I (API-209), Harvard Kennedy School Teaching Fellow for Professor Dan Levy Curriculum Development Assisted with development of Evaluative Sciences and Statistics Reading Group curriculum, Harvard University. June Aug Teaching assistant for course development for Professor Dan Levy. Quantitative Analysis and Empirical Methods (API-201), Harvard Kennedy School Developed case study on the MA Health Care Reform with Dr. Paul Hattis, Public Health and Health Care: Politics, Policies, and Programs (MPH-215), Tufts University School of Medicine. Guest Lectures April 2012 March 2011 Universal Health Insurance and Medicines in Low- and Middle-Income Countries. For Global Issues in Pharmaceutical Policy (IH-820), Boston University School of Public Health. Global Health Research: Topics and Methods. For Research in Global Health and Policy (GHHP- 99), Harvard College. PUBLICATIONS Garabedian 2

3 Peer-reviewed Journals: Garabedian LF, Ross-Degnan D, Soumerai S, Choudhry N, Brown J. Impact of the Massachusetts Individual Mandate and Health Insurance Exchange on Short-Term Enrollment and Adverse Selection. Health Affairs. Under review. Garabedian LF, Chu P, Toh S, Zaslavsky A, Soumerai S. The Invalidity of the Most Common Instrumental Variable Analyses in Comparative Effectiveness Research. Annals of Internal Medicine. Under review. Garabedian LF, Ross-Degnan D, Ratanawijitrasin S, Stephens P, Wagner AK. Impact of universal health insurance coverage in Thailand on sales and market share of medicines for non-communicable diseases: an interrupted time series study. BMJ Open. 2012; 2(6). Available at: Leisinger K, Garabedian LF, Wagner A. Improving Access to Medicines in Low and Middle Income Countries: Corporate Responsibilities in Context. Southern Med Review. 2012; 5(2):3-8. Available at: Faden L, Soumerai S. Comment: Assessment of Changes in Utilization of Health-Care Services After Implementation of a Prior Authorization Policy for Atypical Antipsychotic Agents. The Annals of Pharmacotherapy, 2011; 45:283. Faden L, Vialle-Valentin C, Ross-Degnan D, Wagner A. Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: A systematic review of current evidence. Health Policy. 2011;100(2-3): DiMasi JA, Faden LB. Competitiveness in follow-on drug R&D: a race or imitation? Nature Reviews Drug Discovery. 2011; 10: Cohen J, Wilson A, Faden L. Off-label use reimbursement. Food and Drug Law Journal. 2009;64(2): DiMasi JA, Faden L. Factors associated with multiple FDA review cycles and approval phase times. Drug Information Journal. 2009; 43(2): Faden LB, Milne C-P. Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution? Food and Drug Law Journal. 2008; 63(3): Cohen J, Faden L, Getz K. Mapping biopharmaceutical innovation and diffusion: how the second translational block (T2) shapes drug diffusion. The Open Pharmacology Journal. 2008; 2: Cohen J, Young B, Rochon S, Faden L. Are Medicare plans complying with CMS regulation? Expert Review of Pharmacoeconomics and Outcomes Research. 2008; 8(2): Getz K, Faden L. Racial disparities among clinical investigators. American Journal of Therapeutics. 2008; Jan/Feb: 15(1):3-11. Faden L, Kaitin K. Assessing the performance of the EMEA s centralized procedure: A comparative analysis with the U.S. FDA. Drug Information Journal. 2008; 42(1): Cohen J, Faden L, Predaris S. Patient access to pharmaceuticals: an international comparison. European Journal of Health Economics Sep; 8(3): Cohen J, Cairns C, Paquette C, Faden L. Comparing patient access to pharmaceuticals in the UK and US. Applied Health Economics and Health Policy 2006;5(3): Reichert JM, Faden LB. Therapeutic proteins approved in the European Union BIO-Greece 2005 #15: Garabedian 3

4 Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nature Biotechnology 2005 Sep;23(9): White KS, Faden LB, Covino NA, Gervino EV. Impact of health anxiety and interoceptive fear on pain and healthcare utilization in patients with non-cardiac chest pain. Annals of Behavioral Medicine 2005; 26: S028. Published Reports: Faden L, Vialle-Valentin C, Ross-Degnan D, Wagner A. WHO/HAI Project on Medicine Prices and Availability Policy Review: The Role of Health Insurance in the Cost-Effective Use of Medicines in Low- and Middle-Income Countries. May (Available online at: Faden L, Huskamp H. Medicare Part D Coverage and Reimbursement of Orphan Drugs. In, Rare Diseases and Orphan Products: Accelerating Research and Development (eds. Field M, Boat T), p Institute of Medicine, October (Available online at: Products-Accelerating-Research-and-Development.aspx) Milne C, Faden L. Challenges loom for postmarketing study commitments; benefits unclear. Tufts CSDD Impact Report May/June 2007, Vol. 9, No. 3. Milne C, Faden L. Pediatric study costs increased 8-fold since 2000 as complexity level grew. Tufts CSDD Impact Report March/April 2007, Vol. 9, No. 2. Faden L, Kaitin K. EMEA meets performance goals, but lags U.S. FDA in drug approvals. Tufts CSDD Impact Report January/February 2007, Vol. 9, No. 1 Getz K, Faden, L. CRO contribution to drug development is substantial and growing globally. Tufts CSDD Impact Report January/February 2006, Vol. 8, No. 1. SELECT PRESENTATIONS Impact of Massachusetts Health Care Reform on Short-Term Enrollment and Adverse Selection in Individual Market Plans: Unintended Consequences of the Individual Mandate and Health Insurance Exchange? Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, January Presented at the Harvard Pilgrim Health Care Institute Symposium, Wellesley, MA, December The Impact of Universal Health Insurance Coverage in Thailand on Sales and Market Share of Medicines for Non- Communicable Diseases. Presented (and poster) at the ISPOR International Conference, Washington, DC, June Poster at the International Conference for Improving the Use of Medicine (ICIUM), Antayla, Turkey, November Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, April The Invalidity of Instrumental Variable Analyses in Comparative Effectiveness Research. Poster at the Association for Public Policy Analysis and Management (APPAM) Fall Research Conference, Baltimore, MD, November Presented at the Division of Pharmacoepidemiology and Pharmacoeconomics (DoPE) Seminar, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, May Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, January Garabedian 4

5 Innovative Solutions to Improve Global Medicines Access. Invited panelist at the Boston University School of Public Health Pharmaceutical Symposium, Boston, MA, February Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: A systematic review of current evidence. Presented (and poster) at the International Conference for Improving the Use of Medicine (ICIUM), Antayla, Turkey, November Post Approval Research in the U.S., EU and Japan. Presented at the 2008 Drug Information Association Annual Meeting, Boston, MA. Racial and Gender Disparities among Clinical Investigators. Presented at the 2008 Association for Clinical Research Professionals Annual Meeting, Boston MA. Presented at the 2007 Drug Information Association Annual Meeting, Atlanta, GA Trends in Postmarketing Commitments (PMCs) for FDA-Approved Drugs. Poster at Tufts Research Day 2007, Boston, MA. Impact of Health Anxiety and Interoceptive Fear on Pain and Healthcare Utilization in Patients with Noncardiac Chest Pain. Poster at the 2005 Joint Annual Meeting for the Society of Behavioral Medicine and the Society of Public Health Education, Boston, MA. POLICY-RELATED ACTIVITIES Jan Presented strategies for pharmaceutical pricing policy to the Beijing city government (as part of the Healthy Beijing 2020 project, in collaboration with Dr. Yuanli Lu and other faculty at Tsinghua University) June Nov Nov Collaborated with Dr. Stephen Soumerai to advise the US GAO on the development of an instrument to evaluate the quality of research design for health care and policy studies Participated in the WHO Department of Essential Medicines and Pharmaceutical Policies Technical Briefing Seminar (Geneva, Switzerland) Nov Volunteer research assistant for health insurance reform efforts, Health Care for Massachusetts - Jan Campaign (Cambridge, MA) ANALYTIC SKILLS Statistical programs: SAS, STATA, familiarity with R and SPSS Statistical analyses: regression, generalized linear models, generalized estimating equations, multi-level models, survival analysis, longitudinal analysis, survey analysis Study design: randomized controlled trials, observational studies (i.e., quasi-experimental studies, crosssectional analyses) PROFESSIONAL ACTIVITIES AND AFFILIATIONS 2012 Scientific Committee Member, Second Global Symposium on Health Systems Research 2012-present Peer reviewer: British Medical Journal, Bulletin of the World Health Organization, Health Policy, and Social Science and Medicine 2011-present ISPOR, Member 2009-present Academy Health, Member 2009-present Massachusetts Public Health Association, Member 2007-present American Public Health Association, Member Drug Information Association, Member Tufts Public Health Student Senate (Vice President, ; President, ) American Public Health Association Student Assembly, Liaison for Tufts Tufts Public Health and Professional Degrees Steering Committee, Student Representative Tufts Public Health Academic Advisory Committee, Student Representative Resident Assistant at Boston University Garabedian 5